Adage Capital Partners Gp, L.L.C. Vaxcyte, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $3.89 Million - $5.27 Million	-65,000 Reduced 43.31%	85,088 $5.81 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $816,300 - $1.14 Million	18,000 Added 13.63%	150,088 $9.43 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $3.31 Million - $3.82 Million	72,000 Added 119.82%	132,088 $6.73 Million
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $13 Million - $20.3 Million	-374,912 Reduced 86.19%	60,088 $3 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $13.1 Million - $17 Million	-360,000 Reduced 45.28%	435,000 $16.3 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $14.3 Million - $33.3 Million	695,000 Added 695.0%	795,000 $38.1 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $1.02 Million - $1.34 Million	47,100 Added 89.04%	100,000 $2.4 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $935,272 - $1.41 Million	52,900 New	52,900 $1.15 Million

353

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.86B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.